SPRAVATO® is a prescription nasal spray formulated with esketamine, the S-enantiomer half of the ketamine molecule, and it carries the distinction of being one of the first genuinely new mechanisms of action approved for depression in roughly 30 years. The Food and Drug Administration cleared the medication in March 2019 for adults with treatment-resistant depression, then expanded that approval the following year to cover adults experiencing major depressive disorder along with active suicidal thoughts or behavior. Treatment eligibility typically requires a documented history of trying at least two antidepressants without adequate symptom relief. While esketamine and ketamine come from the same molecular foundation and share the rapid-onset profile that has reshaped psychiatric care, the two diverge sharply in how patients receive them. SPRAVATO® comes packaged as a single-use nasal spray that the patient self-administers under direct clinical observation, while traditional ketamine reaches the bloodstream through an IV line or a muscle injection. Doses must be given inside a REMS-certified treatment facility because the medication can cause temporary effects such as sedation, sensory dissociation, mild hypertension, or coordination issues that warrant in-office monitoring before discharge. Tyler residents and patients across Smith County can access this treatment with the team at Transformative Wellness, located at 4110 Richmond Pl, Texarkana, TX 75503.
SPRAVATO® praised as effective treatment for depression – CBS Miami
What makes SPRAVATO® genuinely different from the antidepressants that came before it is where in the brain it does its work. The familiar SSRI and SNRI categories rely on adjusting how serotonin or norepinephrine cycle through the synapses between neurons, but SPRAVATO® bypasses that strategy entirely. Instead, it acts on glutamate, a neurotransmitter that handles the lion’s share of excitatory signaling across the central nervous system and plays a leading role in everything from learning to memory formation to emotional regulation.
A growing collection of research into the neurobiology of depression points to glutamate signaling abnormalities as a recurring feature of the disorder, with measurable disturbances showing up across regions of the brain involved in mood regulation, motivation, and emotional response. SPRAVATO® appears to address these abnormalities by blocking NMDA receptors and simultaneously stimulating AMPA receptors, a combination that triggers the release of brain-derived neurotrophic factor along with the activation of intracellular kinases that handle downstream signaling, as detailed in research summarized through Duke Health.
Increased BDNF activity is thought to drive the formation of new neurons and influence both the strength and adaptability of synaptic connections, two processes that show up consistently in modern theories about how depression begins to lift at the cellular level. Despite considerable scientific momentum behind these findings, the precise relationship between this molecular cascade and the actual clinical recovery patients experience in their daily lives remains incompletely mapped, and ongoing studies continue to refine the picture year after year.
Be transparent about your full medical history, including any heart conditions, history of stroke, vascular issues, brain injuries, liver problems, or substance use concerns. Share the complete list of medications and supplements you are currently taking, mention any history of psychosis in yourself or close family, and disclose if you are pregnant, planning to become pregnant, or breastfeeding.
SPRAVATO® is the FDA-approved esketamine isomer delivered as a nasal spray and is currently the only form of this treatment with formal regulatory approval for depression. Ketamine infusions are administered intravenously and contain both isomers of the molecule, but their use for depression is considered off-label. Insurance coverage tends to favor SPRAVATO® for that reason.
No. Federal regulations require that every dose be self-administered inside a certified treatment center, with a healthcare provider monitoring you for at least two hours after the dose. The medication never leaves the clinic with the patient.
SPRAVATO® is not recommended during pregnancy or breastfeeding due to potential risks to the developing baby. If you are pregnant, planning a pregnancy, or nursing, your provider will help you weigh alternative treatment paths.
Patients with aneurysmal vascular disease, arteriovenous malformations, a history of intracerebral hemorrhage, or a known hypersensitivity to esketamine or ketamine should not take SPRAVATO®. People with uncontrolled high blood pressure or a recent cardiovascular event also need to be evaluated carefully before starting.
You can discuss with your healthcare provider at the certified SPRAVATO® treatment center the specific personal items you might like to bring with you. These items might include headphones, a music player, a tablet, crossword puzzles or a book to pass the time, and a blanket and pillow to help you relax.
At each visit, your healthcare provider(s) will ask about your symptoms of depression, side effects and whether or not you are experiencing noticeable improvement. In the clinical studies of SPRAVATO®, a standardized scale called the Montgomery-Åsberg Depression Rating Scale was used to track treatment-resistant depression symptoms and response to treatment.
It’s a good idea to ask your healthcare provider(s) at the start of SPRAVATO® treatment how they will be evaluating your response to treatment, and what you can do to help with that. If your referring healthcare provider is not the same provider treating you with SPRAVATO®, you should ask when, and in what way, your new healthcare provider will be letting your referring provider know how your treatments are going and how you are doing.
It is very important to make every effort to stay on the treatment plan that you and your healthcare provider have made. However, if you do miss a treatment, contact your healthcare provider as soon as possible to discuss how they would like to address this situation. Your healthcare provider may decide to change your dose, or dosing frequency, because of missed treatments.
You should ask your healthcare provider(s) what else you might do, beyond taking SPRAVATO® and your oral antidepressant, to help your treatment. If your healthcare provider has included some form of talk therapy in your treatment plan, you should continue that. Some people find that lifestyle changes, including exercise, dietary changes and better sleep can also help decrease depressive symptoms.
You should let all the healthcare providers involved in your care know how your treatments are going and how you are doing – especially if the healthcare provider helping with the overall management of your treatment is not the same provider who is treating you with SPRAVATO®.
Not all patients will respond to SPRAVATO®. Your healthcare provider will evaluate your symptoms of major depressive disorder over the four-week course of treatment to see if you have had satisfactory improvement.
After four weeks, talk to all of the healthcare providers involved in the management of your treatment about appropriate next steps. Do not stop your SPRAVATO® treatments without first discussing your reasons and concerns with your healthcare provider and formulating a treatment plan with them.
If you are using another nasal spray medicine or prescription, such as a nasal steroid or decongestant spray, you should not administer these within the hour before you will be taking SPRAVATO®.
If you have high blood pressure, whether treated or not, you should discuss that specifically with your healthcare provider in deciding whether SPRAVATO® may be right for you. Do not take SPRAVATO® if you have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation) or a history of bleeding in the brain.
SPRAVATO® can increase your blood pressure temporarily – for about four hours – so you will have your blood pressure measured at various times, including before and after taking SPRAVATO®.
If your blood pressure is high before using this medicine, your healthcare provider will decide whether to start the medicine or wait until your blood pressure is lower.
Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision or seizures after taking SPRAVATO®.
Before starting SPRAVATO®, tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO® with certain medicines or alcohol may cause side effects. Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants or monoamine oxidase inhibitor (MAOI) medicines. If you use a nasally administered medication like a nasal steroid or decongestant spray, do not administer it within the hour before you will be taking SPRAVATO®.
Some patients taking SPRAVATO® may experience nausea or vomiting. Because of this, you should avoid eating two hours before, and drinking liquids 30 minutes before, taking SPRAVATO®.
You should discuss your plans for the remainder of the day with your healthcare provider. Because of possible side effects affecting mental alertness and motor coordination, you won’t be able to drive, operate machinery or do anything where you need to be completely alert until the day after a treatment session, following a restful sleep, even if you think you feel well enough to do so. Because of this driving restriction, you will need to plan for your rides on treatment days.
SPRAVATO® may cause sleepiness (sedation or loss of consciousness), fainting, dizziness, spinning sensation, anxiety or feeling disconnected from yourself, your thoughts, feelings and things around you (dissociation). For these reasons, do not drive, operate machinery or do anything where you need to be completely alert until the day after a treatment session, following a restful sleep, even if you think you feel well enough to do so.
The SPRAVATO® Patient Brochure is a helpful resource for learning about SPRAVATO® and treatment-resistant depression.
Download the Patient Discussion Guide to learn more about the SPRAVATO® treatment experience and insurance considerations, and to help guide your conversation about SPRAVATO® with your doctor.
Transformative Wellness is a leading provider of ketamine and vitamin infusion therapies for mental health and chronic pain disorders. Our experienced and compassionate team is dedicated to providing safe, effective, and evidence-based care to empower our patients to achieve optimal wellness.